I. Tanaka

A. Giles, M. Shima, A. Yoshioka, 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Association of anti-idiotypic antibodies with immune tolerance induction for the treatment of hemophilia A with inhibitors.

M. Shima, A. Yoshioka, I. Tanaka, 2004, Haematologica.

Higher recovery of factor VIII (FVIII) with intermediate FVIII/von Willebrand factor concentrate than with recombinant FVIII in a haemophilia A patient with an inhibitor

Tomoko Matsumoto, M. Shima, A. Yoshioka, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates.

M. Shima, A. Yoshioka, J. Giddings, 1996, Thrombosis research.

Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease.

K. Nogami, M. Shima, A. Yoshioka, 2001, Thrombosis research.

Highly Conserved Antigenic Structure of the Factor VIII C2 Domain in Some Mammals

Tomoko Matsumoto, M. Shima, A. Yoshioka, 2005, International journal of hematology.

Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors

A. Giles, M. Shima, A. Yoshioka, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group.

M. Shima, A. Yoshioka, S. Morichika, 1995, International journal of hematology.

Inhibitor which Developed in a Patient with Hemophilia

M. Shima, I. Tanaka, H. Naka, 2000 .

Identification of a factor VIII peptide, residues 2315–2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect

K. Nogami, M. Shima, A. Yoshioka, 1999, British journal of haematology.

Current Status of Hemostatic Treatment for Patients with Hemophilia and Inhibitors in Overseas Guidelines : Towards the Establishment of a Domestic Guideline

M. Shima, I. Tanaka, 2008 .

Abnormal factor VIII Hiroshima: defect in crucial proteolytic cleavage by thrombin at Arg1689 detected by a novel ELISA

M. Shima, A. Yoshioka, S. Morichika, 1994, British journal of haematology.

Human Factor VIII Inhibitor Alloantibodies with a C2 Epitope Inhibit Factor Xa-catalyzed Factor VIII Activation: A new Anti-factor VIII Inhibitory Mechanism

K. Nogami, M. Shima, A. Yoshioka, 2002, Thrombosis and Haemostasis.

Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysis.

K. Nogami, M. Shima, A. Yoshioka, 2001, Blood.

Factor VIII C2 Domain Contains the Thrombin-binding Site Responsible for Thrombin-catalyzed Cleavage at Arg1689 *

T. Koide, K. Nogami, M. Shima, 2000, The Journal of Biological Chemistry.

Successful management of Mallory‐Weiss syndrome in a haemophilia A patient with inhibitor by recombinant activated factor VII

M. Shima, A. Yoshioka, I. Tanaka, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivation.

Hiroshi Suzuki, K. Nogami, M. Shima, 2002, Blood.

Inversions of the Factor VIII Gene in Japanese Patients with Severe Hemophilia A

M. Shima, A. Yoshioka, S. Morichika, 2004, International journal of hematology.

Vertical transmission of hepatitis A virus

M. Shima, A. Yoshioka, I. Tanaka, 1995, The Lancet.

The role of platelet von Willebrand factor in the binding of factor VIII to activated platelets.

K. Nogami, M. Shima, A. Yoshioka, 1998, Thrombosis research.

Factor VIII polypeptide specificity of monoclonal anti‐factor VIII antibodies

M. Shima, A. Yoshioka, H. Fukui, 1988, British journal of haematology.

Surgery of contracture on left knee joint in a patient with congenital factor X deficiency using Konyne.

H. Fukui, I. Tanaka, K. Masuhara, 1986 .

Enzyme-linked immunosorbent assay (ELISA) of factor VIII antigen using a monoclonal antibody devoid of factor VIII inhibitor activity

M. Shima, A. Yoshioka, H. Fukui, 1987 .

Anticoagulant effects of a synthetic peptide containing residues Thr‐2253–Gln‐2270 within factor VIII C2 domain that selectively inhibits factor Xa‐catalysed factor VIII activation

K. Nogami, M. Shima, A. Yoshioka, 2002, British journal of haematology.

Mechanisms of Plasmin-catalyzed Inactivation of Factor VIII

Tomoko Matsumoto, K. Nogami, M. Shima, 2007, Journal of Biological Chemistry.

catalyzed inactivation - activated protein C A novel mechanism of factor VIII protection by von Willebrand factor from

Hiroshi Suzuki, K. Nogami, M. Shima, 2013 .

Dynamic evaluation of hemostasis in the acute phase of Kawasaki disease using comprehensive coagulation functional assays.

Tomoko Matsumoto, K. Nogami, M. Shima, 2019, Thrombosis research.

Efficacy of auxiliary partial orthotopic liver transplantation for cure of hemophilia in a canine hemophilia A model.

A. Giles, M. Shima, A. Yoshioka, 2004, Transplantation Proceedings.

The Assessment of Carrier Status of Canine Hemophilia A in a Hemophilic Colony.

Tomoko Matsumoto, D. Lillicrap, M. Shima, 2002 .

Successful Treatment of Two Brothers with Congenital Afibrinogenemia for Splenic Rupture Using Heat- and Solvent Detergent‐Treated Fibrinogen Concentrates

M. Shima, A. Yoshioka, J. Giddings, 1997, Journal of pediatric hematology/oncology.

Effectiveness and safety of subcutaneous immunotherapy with standardized house dust mite extract for patients under the age of 5 years: A prospective cohort study.

K. Saeki, I. Tanaka, M. Hamada, 2021, Allergology international : official journal of the Japanese Society of Allergology.

Selective factor VIII and V inactivation by iminodiacetate ion exchange resin through metal ion adsorption *

Tomoko Matsumoto, K. Nogami, M. Shima, 2008, British journal of haematology.

Relationship between the Binding Sites for von Willebrand Factor, Phospholipid, and Human Factor VIII C2 Inhibitor Alloantibodies within the Factor VIII C2 Domain

K. Nogami, M. Shima, A. Yoshioka, 2007, International journal of hematology.

Factor V C2 domain contains a major thrombin‐binding site responsible for thrombin‐catalyzed factor V activation

K. Nogami, M. Shima, A. Yoshioka, 2006, Journal of thrombosis and haemostasis : JTH.

Role of factor VIII C2 domain in factor VIII binding to factor Xa.

T. Suzuki, T. Koide, K. Nogami, 1999, The Journal of biological chemistry.

von Willebrand Factor Protects Ca2+-Dependent Structure of the Factor VIII Light Chain.

K. Nogami, M. Shima, A. Yoshioka, 2005 .

Epitope localization of monoclonal antibodies against factor VIII light chain which inhibit complex formation by factor VIII with von Willebrand factor.

M. Shima, A. Yoshioka, S. Kamisue, 1991, International journal of hematology.

An Alloantibody Recognizing the FVIII A1 Domain in a Patient with CRM Reduced Haemophilia A due to Deletion of a Large Portion of the A1 Domain DNA Sequence

K. Nogami, M. Shima, E. Tuddenham, 2000, Thrombosis and Haemostasis.

Anti-factor VIII inhibitor alloantibodies recognizing the A2 domain in the human factor VIII heavy chain poorly bind to porcine factor VIII.

M. Shima, A. Yoshioka, S. Kamisue, 1997, International journal of hematology.

Current practice and future prospects of treatment for patients with congenital hemophilia and inhibitors

I. Tanaka, 2010 .

Factor IX inhibition and epitope localization of factor IX inhibitor antibodies in haemophilia B patients with anaphylactoid reactions

M. Shima, S. Kamisue, I. Tanaka, 1997, Haemophilia : the official journal of the World Federation of Hemophilia.